THE EFFECTOR FUNCTIONS OF ANTIBODIES

Catherine Fridman

BMC423 2009

HUMORAL IMMUNITYAND CELLULAR IMMUNITY

HUMORAL IMMUNITY (ANTIBODIES AND COMPLEMENT) IS USED TO FIGHT AGAINST **EXTRACELLULAR BACTERIA**

CELLULAR IMMUNITY IS USED TO FIGHT AGAINST **INTRACELLULAR MICROBES** (CTL/VIRUSES; TH/INTRACELLULAR BACTERIA)

Emil von Behring, Nobel prize of physiology or medicine in 1901

He discovered that the sera from animals vaccinated with « attenuated » diphteria contained substances, antibodies that protected other animals from living organisms

The first successfull treatment of a child occured in 1891



Figure 4-6
Kuby IMMUNOLOGY, Sixth Edition

ANTIBODIES ARE BIFUNCTIONNAL MOLECULES



Immunology, 7th edition, D.Male et al., Mosby, Elsevier







Immunobiology, 6th edition,, C.Janeway et al., Churchill, Livingstone



Figure 4-7
Kuby IMMUNOLOGY, Sixth Edition

TABLE 4-3 Chain composition of the five immunoglobulin classes in humans

Class*	Heavy chain	Subclasses	Light chain	Molecular formula
IgG	γ	$\gamma1, \gamma2, \gamma3, \gamma4$	κ or λ	$\gamma_2\kappa_2$ $\gamma_2\lambda_2$
IgM	μ	None	κ or λ	$(\mu_2\kappa_2)_n$ $(\mu_2\lambda_2)_n$ $n = 1$ or 5
IgA	α	$\alpha1, \alpha2$	κ or λ	$(\alpha_2\kappa_2)_n$ $(\alpha_2\lambda_2)_n$ $n = 1, 2, 3,$ or 4
IgE	ϵ	None	κ or λ	$\epsilon_2\kappa_2$ $\epsilon_2\lambda_2$
IgD	δ	None	κ or λ	$\delta_2\kappa_2$ $\delta_2\lambda_2$

*See Figure 4-1 for general structures of five antibody classes.

Table 4-3
Kuby IMMUNOLOGY, Sixth Edition



Figure 4-17
Kuby IMMUNOLOGY, Sixth Edition

Isotypes IgG Humaines



Figure 4-18
Kuby IMMUNOLOGY, Sixth Edition

IMMUNOGLOBULINS A

- PRESENT IN MUCOSAL TISSUES
- TWO ISOTYPES IgA1 et IgA2
- MONOMERS IN BLOOD (IgA1/IgA2 = 4)
- DIMERS IN MUCUS (IgA1/IgA2 = 3:2)

Structure of secretory IgA



Figure 4-19a
Kuby IMMUNOLOGY, Sixth Edition

Isotypic determinants



Figure 4-21a
Kuby IMMUNOLOGY, Sixth Edition

Ig isotypes have an heterogeneous distribution in the body



Immunobiology, 6th edition,, C.Janeway et al., Churchill, Livingstone

Isotypes have different functionnal activities

Functional activity	IgM	IgD	IgG1	IgG2	IgG3	IgG4	IgA	IgE
Neutralization	+	–	++	++	++	++	++	–
Opsonization	+	–	+++	*	++	+	+	–
Sensitization for killing by NK cells	–	–	++	–	++	–	–	–
Sensitization of mast cells	–	–	+	–	+	–	–	+++
Activates complement system	+++	–	++	+	+++	–	+	–

Distribution	IgM	IgD	IgG1	IgG2	IgG3	IgG4	IgA	IgE
Transport across epithelium	+	–	–	–	–	–	+++ (dimer)	–
Transport across placenta	–	–	+++	+	++	+/–	–	–
Diffusion into extravascular sites	+/–	–	+++	+++	+++	+++	++ (monomer)	+
Mean serum level (mg ml^{-1})	1.5	0.04	9	3	1	0.5	2.1	3×10^{-5}

Immunobiology, 6th edition,, C.Janeway et al., Churchill, Livingstone

FUNCTIONS OF ANTIBODIES

IgM PRESENT IN BODY FLUIDS
DEFENSES AGAINST INFECTION AND CANCER

IgG PRESENT IN BODY FLUIDS AND TISSUES,
DEFENSES AGAINST INFECTION AND CANCER

IgA PRESENT IN MUCOSAL SURFACES,
NEUTRALIZATION OF PATHOGENS

IgE PRESENT IN TISSUES AND ON VASCULAR ENDOTHELIUM,
ALLERGY, DEFENSES AGAINST HELMINTHS


AgAB
MICROORGANISMS
MICROORGANISMS
CLASSICAL PATHWAY
LECTIN PATHWAY
ALTERNATIVE PATHWAY
COMPLEMENT ACTIVATION
INFLAMMATORY REACTION
MICROORGANISMS OPSONISATION
LYSIS OF BACTERIA


C1q
C1s
C1r



Immunobiology, 6th edition,, C.Janeway et al., Churchill, Livingstone

ANTIBODIES



(from Janeway et al, « Immunobiology », 5th edition Garland ed »)



(from Janeway et al, « Immunobiology », 5th edition Garland ed »)



(from Janeway et al, « Immunobiology », 5th edition Garland ed »)



Cellular and molecular immunology, 4th edition, A.K. Abbas et al., Saunders ed



Cellular and molecular immunology, 4th edition, A.K. Abbas et al., Saunders ed



Basic Immunology, 2nd edition, Abbas and Lichtman, Saunders Elsevier ed

EFFECTOR ROLES OF COMPLEMENT



OTHER FUNCTIONS OF ANTIBODIES : BINDING TO FcGAMMA R

CLASS	FcR TYPE	FcR for TRANSPORT OF Ig
IgM	-	PolylgR
IgG	RFcγ	RFcn
IgA	RFcα	PolylgR
IgE	RFcε	-
IgD	-	-

BIOLOGICAL ACTIVITIES OF Ag-Ab (IgG) COMPLEXES

- **Internalization**
  - **Phagocytosis**
  - **Endocytosis**
- **Cell activation :**
  - **Release of mediators**
  - **Perforin and granzyme release (ADCC)**
  - **Cytokine secretion**
- **Inhibition of Cell activation**


Fab
Fab
Fc
FcγRIII


A
D1
FcγRIII
D2
C_H2
Fc
C_H3
Fc–B
Fc–A
B
D1
FcγRIII
D2
Fc
Fc–B
Fc–A

MOUSE FcγR

FcγRI



Macrophages
Neutrophils

FcγRIIb



B cells
Mast cells

Macrophages
Dendritic cells

FcγRIII



NK cells
Monocytes
Mast cells

FcγRIV



Monocytes
Dendritic cells
Neutrophils

ACTIVATING RECEPTORS

INHIBITORY RECEPTORS

FcγRI **FcγRIII** **FcγRIV** **FcγRIIb1** **FcγRIIb2**



« Immunoreceptor tyrosine activation motif »

(YxxL)(X)n(YxxL)

« Immunoreceptor tyrosine inhibition motif »

ITYSLL

	ACTIVATING FcγR	INHIBITORY FcγR
Dendritic Cells	+	+
Macrophages	+	+
Neutrophils	+	+ ?
Mast cells	+	+
NK cells	+	-
B cells	-	+

ACTIVATING RECEPTORS



T. Takaï,
Nature Rev 2002

INHIBITORY FcγRECEPTORS : DOWN REGULATE ITAM-DEPENDENT RESPONSES



MICE DEFICIENT IN	HYPERSENSITIVITY REACTIONS (II,III) ARTHUS REACTION	AUTOIMMUNE DISEASES (IgG DEPENDENT)
ACTIVATING FcγR	IMPAIRED	RESISTANT
INHIBITORY FcγR	ENHANCED	INCREASED SUSCEPTIBILITY


INHIBITORY FcγR
ACTIVATING FcγR
TOLERANCE
AUTOIMMUNITY

HUMAN FcγR

FcγRI



Macrophages
Neutrophils

FcγRIIA



Macrophages
Monocytes
Dendritic cells

FcγRIIB



B cells
Macrophages
Dendritic cells

FcγRIIIA



NK cells
Monocytes
(γγ, or ζζ)

FcγRIIIB



Neutrophils

FcγRIIA



Macrophages
Dendritic cells

Two alleles in the IgG binding domain H131 or R131

H131 : higher affinity for complexed human IgG2 and IgG3 than R131

R131 : higher affinity for complexed mouse IgG1 than H131

FcγRIIIA



V/P 158

Two alleles in the IgG binding second domain:
V 158 have higher affinity for IgG than P158

FcγR POLYMORPHISMS IN HUMAN AUTOIMMUNE DISEASES

INCREASED SUSCEPTIBILITY TO	FcγRIIa	FcγRIIB	FcγRIIIA	FcγRIIIB
SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)	131 Arg	232 Thr* and promoter	158 Phe NA2	
RHEUMATOID ARTHRITIS (RA)			158 Phe	
WEGENER GRANULOMATOSIS				NA1
GUILLAIN BARRE SYNDROME	131Arg			NA2
MULTIPLE SCLEROSIS	131 Arg			NA2

FcgR in antibody therapy of cancer

Fcγ RECEPTORS CONTROL ANTIBODY THERAPY TO METASTATIC MELANOMA

NORMAL MICE

MICE LACKING ACTIVATING FcγR

MICE LACKING INHIBITORY FcγR



FCGR3A Gene



1q23

exon 6

allele +4985T: 0,6

allele +4985G: 0,4



FcγRIIIa-158F

Phenylalanine

FcγRIIIa-158V

Valine



Homozygous 158F/F: ~ 35 %
Heterozygous: ~ 50 %
Homozygous 158V/V: ~ 15 %

Cartron et al., Blood 2002



Mechanisms of action of MoAbs in anti-tumor immunotherapy

(2) Indirect mechanisms : ADCC



Herceptin (HER2-neu);
Rituxan (CD20);
Campath (CD52)…



Plumas J., LFB, Novembre 2003

Mechanisms of action of MoAbs in anti-tumor immunotherapy

(2) Indirect mechanisms : CDC

Complement-mediated lysis



Herceptin (HER2-neu);
Rituxan (CD20);
Campath (CD52);
Edrecolomab (Ep-CAM)….



Introna M. et al, Blood, Jun 2000

Some anti-tumor Mabs can act independently of the immune system



Mechanisms of action of MoAbs in anti-tumor immunotherapy

(1) Direct mechanisms

Antagonist antibodies
(Erbitux (EGF-R))

Signaling antibodies
(Herceptin (HER2-neu)
Erbitux (EGF-R)
Rituxan (CD20)
Anti-Id mAb)



Inhibition of cellular proliferation
and/or apoptosis

EFFECTOR FUNCTIONS OF IgE

FcεRI: High-affinity IgE receptor



Figure 15-4a
Kuby IMMUNOLOGY, Sixth Edition

Allergen cross-linkage of cell-bound IgE



Figure 15-5a
Kuby IMMUNOLOGY, Sixth Edition



Figure 15-6
Kuby IMMUNOLOGY, Sixth Edition



Figure 4-20
Kuby IMMUNOLOGY, Sixth Edition

TABLE 15-3 Principal mediators involved in type I hypersensitivity

Mediator	Effects
	PRIMARY
Histamine, heparin	Increased vascular permeability; smooth muscle contraction
Serotonin (rodents)	Increased vascular permeability; smooth muscle contraction
Eosinophil chemotactic factor (ECF-A)	Eosinophil chemotaxis
Neutrophil chemotactic factor (NCF-A)	Neutrophil chemotaxis
Proteases (tryptase, chymase)	Bronchial mucus secretion; degradation of blood vessel basement membrane; generation of complement split products
	SECONDARY
Platelet-activating factor	Platelet aggregation and degranulation; contraction of pulmonary smooth muscles
Leukotrienes (slow reactive substance of anaphylaxis, SRS-A)	Increased vascular permeability; contraction of pulmonary smooth muscles
Prostaglandins	Vasodilation; contraction of pulmonary smooth muscles; platelet aggregation
Bradykinin	Increased vascular permeability; smooth muscle contraction
Cytokines	
IL-1 and TNF-α	Systemic anaphylaxis; increased expression of CAMs on venular endothelial cells
IL-4 and IL-13	Increased IgE production
IL-3, IL-5, IL-6, IL-10, TGF-β, and GM-CSF	Various effects (see Table 12-1)

Table 15-3
Kuby IMMUNOLOGY, Sixth Edition

ADCC AGAINST HELMINTHS



CF04

TRANSPORT FUNCTIONS OF ANTIBODIES



Resting mast cell contains granules containing histamine and other inflammatory mediators

Multivalent antigen cross-links bound IgE antibody, causing release of granule contents

Formation of secretory IgA



Figure 4-19b
Kuby IMMUNOLOGY, Sixth Edition



Transport across Placenta

Immunobiology, 6th edition,, C.Janeway et al., Churchill, Livingstone

Ouvrage recommandé

« Immunologie »

6ième édition

Kindt/Kuby/Fridman

Dunod